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Effects of stable. selective A, adenosine receptor agonist (N6_cyc lohexyl-
2'-0-methyladenosine) SDZ WAG 994 were investigated in a randomized,
double-blind, placebo-controlled, parallel group. multicenter study. After
baseline hemodynamic and neurohormone data were obtained in 50 patients
(mean age 56 years) with left ventricular dysfunction (mean EF 30%). who
were NYHA Class I (32%) or II (68%). they received either I, 2 or 5 mg of
SDZ WAG 994 or placebo orally. Hemodynamic data were collected every 30
minutes for 4 hours and then every 2 hours for 20 hours. Neurohormones
and plasma drug concentration were measured 2 hours after dosing.
The active drug was clinically well tolerated as there were no significant
differences comparing adverse events reported with placebo and the 3 ac-
tive drug doses. No important effects were seen on systolic, right atrial. pul-
monary artery or pulmonary artery wedge pressures, cardiac index, or heart
rate. The PR interval increased slightly with the 5 mg dose (176 to 193 msec
at 2 hrs). Atrial natriuretic peptide (ANP) levels increased significantly (216
± 137 to 407 ± 146 pgfmL, p < 0.01) with the 5 mg dose and increases
of lesser magnitude occurred with 1 and 2 mg doses. Interestingly, plasma
norepinephrine also increased with the 5 mg dose (477 ± 243 to 618 ± 237
pglmL, p < 0.01). No significant changes occurred in plasma renin activity Or
epinephrine levels.
In summary, selective A, adenosine receptor agonism, evidenced by an in-
crease in PR interval and plasma ANP. was safely achieved for several hours
in patients with LV dysfunction. Significant neurohormonal effects were ob-
served with no important hemodynamic changes. Both A, adenosine ag-
onism and ANP have been shown to attenuate hypoxic cell damage and
vasoconstriction and this agent could have clinical utility in ischemic heart
disease.
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Previous investigators have demonstrated that mental stress can induce my-
ocardial ischemia in selected patients with coronary disease manifested by
new wall motion abnormalities on radionuclide ventriculography. It is un-
known whether such ischemia is due to coronary vasoconstriction or to in-
creased myocardial O2 demand. We studied the effect of nifedipine GITS
and atenolol as single-agent therapy on mental stress-induced ischemia
in a double-blind. placebo-controlled, three-way crossover trial in 16 pa-
tients with stable angina. Each patient received maximally tolerated doses
of nifedipine (mean daily dose: 88 mg). atenolol (mean daily dose: 91 mg)
or placebo during each of 3 4-week treatment phases. At the end of each
phase. patients underwent a mental stress procedure (Stroop color word
test, mental arithmetic. and stress interview) with skin conductance moni-
tored to gauge physiologic arousal. Left ventricular wall motion was graded
in each of 5 regions using a scale from 3 (normal) to -1 (dyskinesis), and by
regional ejection fraction. The segment with the largest deterioration in wall
motion during placebo therapy was determined, and the effects of nifedipine
and atenolol on this segment were compared. Results: Mental stress caused
a significant increase in skin conductance levels, with peak values similar on
each therapy. Therapy with either nifedipine or atenolol prevented a dete-
rioration in wall motion score (-0.6 for placebo; 0.0 for nifedipine. 0.0 for
atenolol, each p < 0.01 vs. placebo). while only nifedipine prevented a sig-
nificant decrease in regional ejection fraction (-13.0% on placebo; -5.6%
for atenolo!. p = 0.08 vs. placebo; -1.9% on nifedipine, p = 0.01 vs placebo,
p ~ 0.4 vs. atenolol). The rate pressure product (heart rate x systolic blood
pressure. RPP) at peak mental stress (Le.. peak myocardial 02 demand)was
15.792 on placebo, and was reduced only by atenolol (12,287, p = 0.001).
but not by nifedipine (15,185, p ~ NS). Conclusion: Both nifedipine GITS
and atenolol are effective at preventing mental stress-induced ischemic wall
motion abnormalities. although the mechanisms may be different. Nifedipine
improved reg'lonal wall motion without reducing RPP. and thus may have pre-
vented mental stress-induced coronary vasoconstriction. Atenolol improved
regional wall motion and reduced RPP. and thus may have been effective by
reducing myocardial O2 demand.
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Long-term Effects of Amlodlpine and
Isosorblddinltrate on Exercise-Induced and
Ambulatory Ischaemia In Patients with Stable
Angina Pectoris
Enalapril Does not Affect Ischemia During
Short·term Treatment in Stable Angina Pectoris
Irrespective of Its Effect on Blood Pressure
Whereas ACE inhibition acutely reduces myocardial ischemia (MI) through
neuroendocrine modulation and, after long-term treatment (1 year), affects
ischemic events in LV dysfunction. the short-term anti ischemic properties in
chronic, stable anginal patients and normal LV function are debated. As a
pro-ischemic effect may be explained by lowering coronary artery perfusion
pressure, the effects of enalapril (E) 10 mg b.i.d. on ischemia in relation to
blood pressure (BP). and placebo b.Ld. were compared in 27 patients with
chronic exercise-induced angina pectoris in a double-blind cross-over trial
with 2 treatment periods of 2 weeks each. Exercise performance was as-
sessed using treadmill exercise tests. No period or treatment sequence ef-
fects were observed for BP. heart rate and exercise performance. After treat-
ment with E. resting systolic and diastolic BP were 7% and 6%, respectively,
lower compared to placebo. During maximal exercise. systolic BP and rate-
pressure product (RPP) were similar during both treatments, whereas dias-
tolic BP was 6% less with E. Maximal workload was comparable after both
treatment periods. No differences between treatment were seen with regard
to exercise duration. time to angina. maximal ST-depression (0.2 mV in both
groups) and time to 0.1 mV ST-depression. When patients were divided into
2 groups according to BP response on an initial dose of 10 mg E, 11 pts:::
20 mmHg and 16 pts < 16 mmHg, still no differences during exercise were
found. Thus. in stable chronic exercise-induced angina. short-term E does
not decrease myocardial ischemia, irrespective of first-dose BP response.
Also, no pro-ischemic effects as a result of lowering coronary artery perfu-
sion pressure were observed.
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The autonomic nervous system plays an important role in the occurrence of
symptomatic and silent myocardial ischemia (MI) during daily life. Analysis of
heart rate variability (HRV) is a non-invasive tool which provides information
on autonomic control. We investigated if analysis of HRV can be used to pre-
dict the efficacy of drug treatment of MI in a double-blind, cross-over study.
Twenty eight patients with stable angina pectoris, proven coronary artery
disease and MI during Holter monitoring received metoprolol controlled re-
lease 200 mg once daily and diltiazem 60 mg 4 times daily. After a placebo
phase and after each treatment period. 72 hour Holter recordings were per-
formed for analysis of HRVand MI. HRV analysis included standard deviation
Rolf Steffensen, Thomas Melchior, Jan Bech. Henrik Nissen. Bennedicte Haastrup.
Peer Grande, Verner Rasmussen. J",gen F. Hansen, Knud Skagen,
Torben Haghfelt. University of Copenhagen and University of Odense, Denmark
Once-daily administration of 10 rng amlodipine has been compared with two
daily doses of 40 mg sustained-release isosorbiddinitrate (ISDN) in 59 pa-
tients with stable angina, using a randomized, double-blind, double-placebo.
crossover study design. Nine patients dropped out due to side effects (3 dur-
ing amlodipine and 6 during ISDN therapy). and one patient was excluded for
technical reasons.
A maximal symptom limited supine bicycle tolerance test and a 48 h am-
bulatory ECG monitoring were performed at the end of each 5 week period
of therapy. During exercise, exercise time, time to onset of angina, and time
to onset of ischaemia, Le., 1 mm ST segment depression were measured.
During ambulatory monitoring. number of anginal episodes and duration per
hour of ST deviation were assessed.
Amlodipine significantly prolonged time to angina (320 ± 155 vs 304 ±
126 sec; p < 0.05) and time to ischaemia (292 ± 153 vs 232 ± 126 sec;
p < 0.001). when compared with ISDN, while exercise time was similar for
both treatments. Furthermore, amlodipine reduced anginal episodes (1.2 ±
1.6 vs 2.4 ± 3.0 attacksf48 h; p < 0.001). whereas. no difference was found
between amlodipine and ISDN in duration of ST deviation during ambulatory
monitoring.
In conclusions, addressing the long-term treatment of patients with stable
angina pectoris. once-daily dosing of amlodipine appears to be more effec-
tive than ISDN, as determined by its anti-anginal and anti-ischaemic effects
during exercise tolerance testing and ambulatory ECG monitoring.
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